Clinical trial
Sildenafil For Meniere's Disease
NCT00145483 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00145483 |
|---|---|
| Title | Sildenafil For Meniere's Disease |
| Official title | A Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study Of The Efficacy and Safety Of Sildenafil Given For The Acute Treatment Of Meniere's Disease |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Meniere's Disease |
| Intervention type | Drug |
| Interventions | Sildenafil |
| Enrollment | 163 |
| Start date | Jun 18, 2002 |
| Primary completion | Nov 8, 2006 |
| Completion | Nov 8, 2006 |
| First posted | Sep 5, 2005 |
| Last update posted | Feb 1, 2021 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: